GTx, Inc.
http://www.gtxinc.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From GTx, Inc.
HAYA To Complement Lilly’s Metabolic Disease Efforts With Long Non-Coding RNA
HAYA, a pioneer in lncRNA, is teaming up with Lilly to discover novel targets and programmable RNA therapies for obesity and metabolic disorders.
Bayer Returns To Cancer Drug In-Licensing With NextRNA Deal
Oncology is key to the German group’s turnaround plans and an early-stage licensing pact with NextRNA is the first cancer deal by its new business development leader.
Asia Deal Watch: Chugai Extends Relationship With Helsinn
Plus deals involving Kissei/JWP, Shionogi/Cilcare, Takeda/Torrent, Genome & Co./Debiopharm, Kaken/J&J, CStone/Ewopharma, MediLink/BioNTech and more.
Ipsen In No Doubt About Its Abilities To Launch
Sales of the French firm’s new products missed consensus forecasts but CEO David Loew is confident that those drugs and the therapies that are close to the market will be commercial successes.
Company Information
- Other Names / Subsidiaries
-
- Oncternal Therapeutics, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice